149104-89-2

Usage

InChI:InChI=1/C8H9BrO/c1-6-4-7(5-10)2-3-8(6)9/h2-4,10H,5H2,1H3

Upstream product

• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 
• 160313-69-9 ethyl 3-methyl-4-bromobenzoate 
• 78775-11-8 3-methyl-4-bromobenzaldehyde 

Downstream Products

• 27561-51-9 1-bromo-4-(bromomethyl)-2-methylbenzene 
• 591775-18-7 3-(4-hydroxymethyl-2-methyl-phenyl)-acrylic acid methyl ester 
• 160504-66-5 2-((4-bromo-3-methylbenzyl)oxy)tetrahydro-2H-pyran 
• 1159197-86-0 4-bromo-3-methylbenzyl trichloroacetimidate 
• 1283146-88-2 (S)-methyl 2-(1-(4-(4-bromo-3-methylbenzyloxy)phenyl)pyrrolidin-2-yl)acetate 
• 1283143-29-2 (S)-2-(1-(4-(4-bromo-3-methylbenzyloxy)phenyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-89-3 methyl 2-((2S)-1-(4-((2'-fluoro-5'-methoxy-2-methylbiphenyl-4-yl)methoxy)phenyl)pyrrolidin-2-yl)acetate 
• 56917-40-9 3-methyl-4-phenyl-1-ethynylbenzene 
• 1349733-78-3 5-bromo-3-(5-(4-(bromomethyl)-2-methylphenyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-amine 
• 1349733-76-1 methyl 2-methyl-4-((triisopropylsilyloxy)methyl)benzoate 
• 1349733-77-2 2-methyl-4-(triisopropylsilyloxymethyl)benzoic acid 
• 1349733-74-9 (4-bromo-3-methylbenzyloxy)triisopropylsilane 
• 1563057-80-6 N-(4-bromo-3-methylbenzyl)-3,6,12,15-tetrathia-9-monoazaheptadecane 
• 948350-91-2 (4-bromo-3-methylphenyl)methyl methanesulfonate 

Relevant academic research and scientific papers

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Scalable synthesis of [8]cycloparaphenyleneacetylene carbon nanohoop using alkyne metathesis

Large scale synthesis of cycloparaphenyleneacetylenes has been challenging due to low macrocyclization yields and harsh aromatization methods that often decompose strained alkynes. Herein, acis-stilbene-based building block is subjected to alkyne metathes

STAT DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds

Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors

Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low

COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL- cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS

Compounds, pharmaceutical formulations, and methods of treating inflammatory conditions are disclosed.(F)

FLUORESCENT PROBES FOR DETECTION OF COPPER

The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.